Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 5, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,605,000 ordinary shares.
- Purchase Price: 1,310.928 pence per share.
- Treasury Shares Held: 380,712,158 shares (representing 6.74% of total voting rights).
- Shares in Issue: 5,641,789,988 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the September 5, 2007 transaction. The total number of shares held in Treasury now represents 6.74% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,641,789,988) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (380,712,158) and its impact on the total voting rights percentage (6.74%).
- Note that this filing is a notification of a completed share buyback and does not contain quarterly or annual financial results.